About Us
ACADIA Pharmaceuticals (NASDAQ: ACAD) is a biopharmaceutical company focused on innovative small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. We have a pipeline of product candidates led by pimavanserin, which is in Phase III development as a potential first-in-class treatment for Parkinson's disease psychosis.
All of ACADIA's product candidates emanate from discoveries made using our proprietary drug discovery platform. We have assembled a strong team of industry-experienced executives to lead the development of our product candidates and we complement this team with a group of world-class scientific and clinical advisors.
back to top